Evaluation of Breathe NIOV System on Work of Breathing in Chronic Obstructive Lung Disease Patients

Sponsor
Breathe Technologies, Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT01596023
Collaborator
Tufts Medical Center (Other)
14
1
1
19
0.7

Study Details

Study Description

Brief Summary

The Breathe Ventilator is a lightweight, wearable ventilator that has received U.S. FDA clearance for use in patients with respiratory difficulty. The investigators believe that the Breathe NIOV system will reduce the work of the diaphragm and breathing by providing added tidal volume and oxygen. This will be a study in 14 patients with severe-to-very severe chronic obstructive lung disease (COPD) to assess their work of breathing while using the NIOV system as measured by esophageal and stomach pressures.

Condition or Disease Intervention/Treatment Phase
  • Device: Breathe NIOV Ventilator
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
14 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
Single (Participant)
Primary Purpose:
Prevention
Official Title:
Evaluation of Effect of Breathe Ventilation System on Work of Breathing in COPD Patients
Study Start Date :
May 1, 2012
Actual Primary Completion Date :
Dec 1, 2013
Actual Study Completion Date :
Dec 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Experimental: NIOV Ventilator

Breathe NIOV Ventilator under various volume augmentation settings

Device: Breathe NIOV Ventilator
Portable, non invasive open ventilation system

Outcome Measures

Primary Outcome Measures

  1. Pressure time product of the diaphragm (PTPdi) during use of the Breathe Ventilation System [10 min]

    Calculated using the area of the transdiaphragmatic pressure for the duration of inspiration

Secondary Outcome Measures

  1. Changes in PTP of the esophagus (PTPes), PTP per minute (PTPdi/min and PTPes/min [10 Min]

    Changes in PTP of the esophagus (PTPes), PTP per minute (PTPdi/min and PTPes/min)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Subject is >18 years of age at time of consent.

  2. Subject has diagnosis of severe COPD (GOLD stage III or IV) as demonstrated by a FEV1 < 50% predicted and FEV1/FVC ratio < 70% predicted.

  3. Subject has increased inspiratory muscle work of breathing as evidenced by palpable sternocleidomastoid muscle contraction during inspiration

Exclusion Criteria:
  1. Subject has acute exacerbation of COPD - within 1 week of acute hospitalization

  2. Subject has respiratory rate at rest > 28/min

  3. Subject requires > 5 L/min nasal O2/min to maintain O2sat > 90%

  4. Subject has severe dyspnea at rest

  5. Subject has swallowing disorders or chronic aspiration, prior esophageal surgery, or any other condition that would place the subject at risk during balloon placement.

  6. Subject has history of pneumothorax secondary to lung bullae.

  7. Subject is too cognitively impaired to give subjective ratings for visual analog scale

  8. Subject has sensitivity or an allergy to lidocaine

  9. Subject has known history of oxygen intolerance.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Tufts Medical Center Boston Massachusetts United States 02111

Sponsors and Collaborators

  • Breathe Technologies, Inc.
  • Tufts Medical Center

Investigators

  • Principal Investigator: Nicholas Hill, MD, Tufts Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Breathe Technologies, Inc.
ClinicalTrials.gov Identifier:
NCT01596023
Other Study ID Numbers:
  • CP-00-0033
First Posted:
May 10, 2012
Last Update Posted:
Jan 15, 2014
Last Verified:
Jan 1, 2014
Keywords provided by Breathe Technologies, Inc.
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 15, 2014